⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22656957 | 0.78 | — | — | |
| SCHEMBL28861155 | 0.74 | — | — | |
| SCHEMBL508798 | 0.70 | — | — | |
| Propane SCHEMBL3139620 | 0.63 | — | — | |
| Propane SCHEMBL1332567 | 0.63 | — | — | |
| Propane SCHEMBL31613262 | 0.63 | — | — | |
| SCHEMBL508125 | 0.63 | — | — | |
| SCHEMBL174801 | 0.61 | — | — | |
| Ethylamine SCHEMBL4840928 | 0.60 | — | — | |
| Alcohol SCHEMBL1332633 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151346-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230295124-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2023-09-21 | — | — | US | disclosed |
| WO-2023178285-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111526890-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022052926-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 广州再极医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| CN-109311872-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-111556871-A | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111526890-A | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111465410-A | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-2751084-B1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | EUDIS BIOTECH LLC (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2751084-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | Apac Pharmaceutical LLC. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2013032522-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | APAC PHARMACEUTICAL LLC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |